Edaravone Guards Dopamine Neurons in a Rotenone Model for Parkinson's Disease

3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone), an effective free radical scavenger, provides neuroprotection in stroke models and patients. In this study, we investigated its neuroprotective effects in a chronic rotenone rat model for Parkinson's disease. Here we showed that a five-week treatment with edaravone abolished rotenone's activity to induce catalepsy, damage mitochondria and degenerate dopamine neurons in the midbrain of rotenone-treated rats. This abolishment was attributable at least partly to edaravone's inhibition of rotenone-induced reactive oxygen species production or apoptotic promoter Bax expression and its up-regulation of the vesicular monoamine transporter 2 (VMAT2) expression. Collectively, edaravone may provide novel clinical therapeutics for PD.

[1]  K. G. Rajesh,et al.  Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression. , 2003, American journal of physiology. Heart and circulatory physiology.

[2]  W. Schmidt,et al.  l-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats , 2004, Behavioural Brain Research.

[3]  Masato Naraoka,et al.  EFFECT OF A FREE RADICAL SCAVENGER, EDARAVONE, IN THE TREATMENT OF PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE , 2009, Neurosurgery.

[4]  D. Sulzer,et al.  Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.

[5]  M. Amalric,et al.  Targeting Group III Metabotropic Glutamate Receptors Produces Complex Behavioral Effects in Rodent Models of Parkinson's Disease , 2007, The Journal of Neuroscience.

[6]  八木 謙次.  Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator , 2009 .

[7]  Beate Ritz,et al.  Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. , 2006, Human molecular genetics.

[8]  C. Glatt,et al.  High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  W. Koek,et al.  WIN55,212‐2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model of Parkinson’s disease , 2009, The European journal of neuroscience.

[10]  G. Uhl,et al.  SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. , 2005, Human molecular genetics.

[11]  H. Fukui,et al.  The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis? , 2008, Trends in Neurosciences.

[12]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[13]  F. Fonnum,et al.  Relationship between lipophilicity of C6-10 hydrocarbon solvents and their ROS-inducing potency in rat cerebellar granule cells. , 2002, Neurotoxicology.

[14]  W. Schmidt,et al.  Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. , 2009, Toxicology and applied pharmacology.

[15]  W. Schmidt,et al.  Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats , 2002, Behavioural Brain Research.

[16]  Peter T Lansbury,et al.  Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. , 2008, The Journal of clinical investigation.

[17]  Todd B. Sherer,et al.  An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage , 2002, The Journal of Neuroscience.

[18]  T. Ikeda,et al.  Short-Term Administration of a New Free Radical Scavenger, Edaravone, Is More Effective Than its Long-Term Administration for the Treatment of Neonatal Hypoxic–Ischemic Encephalopathy , 2005, Stroke.

[19]  Chunnuan Chen,et al.  Long-term efficacy and safety of human umbilical cord mesenchymal stromal cells in rotenone-induced hemiparkinsonian rats. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  Tao Zhang,et al.  Oxidative stress and apoptosis induced by nanosized titanium dioxide in PC12 cells. , 2010, Toxicology.

[21]  M. Kameda,et al.  Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons , 2008, BMC Neuroscience.

[22]  A. Baba,et al.  Nitric oxide‐induced apoptosis in cultured rat astrocytes: Protection by edaravone, a radical scavenger , 2007, Glia.

[23]  J. Dubochet,et al.  The mammalian central nervous synaptic cleft contains a high density of periodically organized complexes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Todd B. Sherer,et al.  Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.

[25]  A. Baba,et al.  Edaravone (3-Methyl-1-phenyl-2-pyrazolin-5-one), a Radical Scavenger, Prevents 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Neurotoxicity in the Substantia Nigra but Not the Striatum , 2007, Journal of Pharmacology and Experimental Therapeutics.

[26]  Fei Xu,et al.  Knockout of the Vesicular Monoamine Transporter 2 Gene Results in Neonatal Death and Supersensitivity to Cocaine and Amphetamine , 1997, Neuron.

[27]  T. Tamiya,et al.  Edaravone Attenuates Brain Edema and Neurologic Deficits in a Rat Model of Acute Intracerebral Hemorrhage , 2008, Stroke.

[28]  N. Xiong,et al.  VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson’s disease , 2011, Gene Therapy.

[29]  P. Gubellini,et al.  Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  T. Yoshikawa,et al.  Alkoxyl radical-scavenging activity of edaravone in patients with traumatic brain injury. , 2006, Journal of neurotrauma.

[31]  Limei Zhang,et al.  Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells , 2005, Neurobiology of Disease.

[32]  M. Watabe,et al.  Mitochondrial Complex I Inhibitor Rotenone Inhibits and Redistributes Vesicular Monoamine Transporter 2 via Nitration in Human Dopaminergic SH-SY5Y Cells , 2008, Molecular Pharmacology.

[33]  D Spiegelman,et al.  Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk , 2002, Neurology.

[34]  C. Warren Olanow,et al.  The scientific and clinical basis for the treatment of Parkinson disease (2009) , 2009, Neurology.

[35]  M. Smith,et al.  Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. , 2007, CNS & neurological disorders drug targets.

[36]  Y. Nomura,et al.  Edaravone Protects against Hypoxia/Ischemia-Induced Endoplasmic Reticulum Dysfunction , 2004, Journal of Pharmacology and Experimental Therapeutics.

[37]  G. Hu,et al.  Edaravone protects against MPP+‐induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway , 2008, Journal of neurochemistry.

[38]  B. Xiao,et al.  Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats , 2007, Neurotoxicity Research.

[39]  P. Beart,et al.  Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury. , 2010, Journal of Alzheimer's disease : JAD.

[40]  C. Nito,et al.  Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. , 2005, European journal of pharmacology.

[41]  Sheng-gang Sun,et al.  alpha-Synuclein redistributed and aggregated in rotenone-induced Parkinson's disease rats. , 2006, Neuroscience bulletin.

[42]  Ji Hyun Choi,et al.  Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease , 2010, Brain Research.

[43]  Dolores Baksh,et al.  Human Umbilical Cord Perivascular (HUCPV) Cells: A Source of Mesenchymal Progenitors , 2005, Stem cells.

[44]  R. Soulimani,et al.  Evidence that oxidative stress is linked to anxiety-related behaviour in mice , 2008, Brain, Behavior, and Immunity.

[45]  Chunnuan Chen,et al.  Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson's disease , 2012, Neurobiology of Aging.

[46]  S. Nakano,et al.  Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice , 2008, Experimental Neurology.

[47]  Fang Wang,et al.  Stereotaxical Infusion of Rotenone: A Reliable Rodent Model for Parkinson's Disease , 2009, PloS one.

[48]  Zhenxin Zhang,et al.  Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai , 2005, The Lancet.

[49]  C. Rowe,et al.  In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133 , 2010, Journal of Nuclear Medicine.

[50]  T. Satou,et al.  The Novel Free Radical Scavenger, Edaravone, Increases Neural Stem Cell Number Around the Area of Damage Following Rat Traumatic Brain Injury , 2009, Neurotoxicity Research.

[51]  S. Nagahiro,et al.  Edaravone, a Free Radical Scavenger, Inhibits MMP-9–Related Brain Hemorrhage in Rats Treated With Tissue Plasminogen Activator , 2009, Stroke.

[52]  棟方 聡.  Effect of a free radical scavenger, edaravone in the treatment of patients with aneurysmal subarachnoid hemorrhage , 2009 .

[53]  A. Kanthasamy,et al.  Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease. , 2007, Pharmacology & therapeutics.